LL-37 side effects reported so far include injection-site redness, flu-like feelings and fatigue, plus bigger questions about inflammation, autoimmunity and tumor growth. TelosRX explains what the research and the FDA actually say.
LL-37 has a great origin story. It's part of your built-in immune defense. It kills bacteria, calms some inflammation and helps wounds close in lab models.
So why is it one of the most debated peptides online? Because the same molecule that defends you can also fuel inflammation. Context changes everything. Here's what you need to know about LL-37 side effects before it comes up with a provider.
What Is LL-37? A 60-Second Refresher
LL-37 is the only human cathelicidin (a family of antimicrobial peptides). It's 37 amino acids long and starts with two leucines. Hence the name: L, L, 37.
Your body cuts it from a larger protein called hCAP18. A 2006 review in Biochimica et Biophysica Acta describes where it's made:
- White blood cells called neutrophils.
- Skin cells, especially after injury or infection.
- The lining of your gut and airways.
Vitamin D helps switch on the gene that makes it. That's a big reason it gets attention. For the full background, read our LL-37 cathelicidin research summary.
LL-37 Side Effects at a Glance
Here's every concern covered below, sorted by how strong the evidence is. "Reported" means it shows up in clinic materials or user accounts, not controlled trials.
| Possible effect | Source of evidence | How common | Evidence strength |
|---|---|---|---|
| Injection-site redness, burning or swelling | Clinic and user reports | Reported as common | Low (anecdotal) |
| Flu-like symptoms, fatigue | Clinic and user reports | Reported occasionally | Low (anecdotal) |
| Skin inflammation (psoriasis, rosacea links) | Human tissue and animal studies | Unknown with outside use | Moderate (mechanism) |
| Autoimmune activation | Lab and patient-tissue studies | Unknown | Moderate (mechanism) |
| Damage to human cells at high levels | Lab studies | Dose-dependent in cells | Moderate (preclinical) |
| Tumor growth in some tissues | Preclinical studies; FDA review | Unknown | Low to moderate (preclinical) |
| Male reproductive effects | Nonclinical findings cited by FDA | Unknown | Low (preclinical) |
| Immune reaction to the peptide itself | FDA assessment | Unknown | Theoretical, flagged by FDA |
Notice the pattern. The "How common" column mostly says "unknown." That's the honest state of LL-37 research.
Injection-Site Reactions
The most commonly reported issue is local. People describe redness, burning, stinging or swelling where the shot went in.
This makes sense biologically. LL-37 attracts immune cells and triggers local signaling. A little inflammation at the site is part of how it works.
- Reactions are usually described as short-lived.
- Rotating injection sites is the standard advice for any injectable.
- Spreading redness, heat or pus could signal infection and needs prompt care.
Flu-Like Symptoms and Fatigue
Some users report feeling run-down after doses. Mild aches, low energy or a "fighting something off" feeling come up in accounts.
There's no controlled human data on how often this happens. It may reflect immune activation. It may also reflect the reason someone sought LL-37 in the first place, like a lingering infection.
Symptoms that build over time, or include fever, aren't something to push through. Report them to a provider.
The Inflammation Paradox: Psoriasis and Rosacea
This is the big one. LL-37 can calm some inflammation and ignite other kinds. Researchers have linked it directly to two skin conditions.
Psoriasis
A landmark 2007 study in Nature found LL-37 binds fragments of the body's own DNA. That complex activates immune cells called plasmacytoid dendritic cells. They then release interferon, an inflammatory signal that drives psoriasis plaques.
Rosacea
A 2007 study in Nature Medicine found people with rosacea had abnormally high cathelicidin levels in their skin. When researchers injected LL-37 into mouse skin, it produced rosacea-like redness and inflammation.
The takeaway: if you have psoriasis, rosacea or eczema-prone skin, extra LL-37 could theoretically make things worse.
LL-37 and Autoimmune Conditions
The same DNA-binding trick shows up beyond skin. A 2013 review in the Journal of Immunology, titled "Little peptide, big effects," lays out LL-37's role in autoimmune disease.
Research has linked LL-37 activity to lupus, rheumatoid arthritis and atherosclerosis (artery plaque). In these settings, it may help the immune system react against the body's own tissue.
None of this proves a dose of LL-37 causes autoimmunity. But it's a clear reason for caution in anyone with an autoimmune history.
Effects on Human Cells
LL-37 kills bacteria by punching holes in their membranes. At higher concentrations, lab studies show it can damage human cell membranes too.
Bacteria are more vulnerable than your cells, which is why it works as a defense. But the margin isn't unlimited. Lab dishes also don't match what happens inside a body, so real-world relevance is unclear.
Cancer Questions: A Two-Way Street
Preclinical research shows LL-37 behaves differently by tissue. In some cancer models, such as ovarian, breast and lung, it appeared to promote tumor growth. In others, such as some gut cancers, it appeared to suppress it.
This split is why the FDA flagged it. Its review notes LL-37 "can be protumorigenic in some tissues," meaning it may encourage tumors. Anyone with a cancer history should discuss this carefully with their oncologist.
What the FDA Has Said About LL-37
LL-37 is not FDA-approved for any use. The FDA placed cathelicidin LL-37 on its list of bulk drug substances that may present significant safety risks in compounding. Its stated concerns:
- Possible immunogenicity, meaning the body may mount an immune response to the peptide.
- Complexities with peptide-related impurities and ingredient characterization.
- Not enough safety information to know whether it causes harm in humans.
- Nonclinical findings suggesting effects on male reproduction.
- Possible tumor-promoting effects in some tissues.
This listing shapes whether and how a licensed pharmacy may compound it. Our explainer on peptide FDA categories walks through what these lists mean.
What the Human Trials Show
Controlled human data are thin, but not zero. A 2014 randomized, placebo-controlled trial tested topical LL-37 on hard-to-heal venous leg ulcers.
- It was a small phase I/II study.
- LL-37 was applied to the wound surface, not injected.
- The authors reported it was well tolerated, with no safety concerns at the doses tested.
That's encouraging for topical wound use. It says little about injected LL-37, longer use or other conditions.
Quality and Sourcing Risks
Many LL-37 products online are sold "for research use only." That label means no one checked them for human use. Risks include wrong dose, contamination and bacterial toxins.
Peptide quality problems can cause reactions that have nothing to do with LL-37 itself. That makes side effects even harder to interpret.
Who Should Be Most Cautious
Based on the research above, these groups have the strongest reasons to avoid or carefully review LL-37:
- People with psoriasis, rosacea or other inflammatory skin conditions.
- People with lupus, rheumatoid arthritis or other autoimmune disease.
- Anyone with a current or past cancer.
- People who are pregnant, breastfeeding or trying to conceive.
- Anyone using immune-suppressing medications.
Safer Ways to Explore Immune and Inflammation Support
If LL-37 caught your interest because of gut or skin inflammation, it's worth knowing the alternatives. Your body's own LL-37 rises with adequate vitamin D. Our guide on how to increase LL-37 naturally covers that route.
Other peptides are studied for inflammation too. See how TelosRX approaches KPV, a peptide studied in gut and skin inflammation models. KPV is not FDA-approved. Any prescription is subject to medical approval by a licensed provider after an asynchronous online evaluation.
Frequently Asked Questions
What are the side effects of LL-37?
Reported LL-37 side effects include injection-site redness, burning and swelling, plus occasional flu-like symptoms and fatigue. Research also links LL-37 to inflammatory skin conditions like psoriasis and rosacea, autoimmune activity and possible tumor promotion in some tissues. Controlled human safety data remain limited.
Is LL-37 safe?
Its safety in humans isn't well established. A small 2014 trial found topical LL-37 well tolerated on leg ulcers. But the FDA lists cathelicidin LL-37 as a substance that may present significant safety risks in compounding, citing immunogenicity, impurities and limited safety data.
Can LL-37 cause inflammation?
Yes, in some settings. LL-37 can bind the body's own DNA and activate immune cells that release interferon. A 2007 Nature study tied this process to psoriasis. Another 2007 study linked high cathelicidin levels to rosacea. It can calm some inflammation and drive other kinds.
Is LL-37 FDA approved?
No. LL-37 is not FDA-approved for any condition. The FDA has placed cathelicidin LL-37 on its list of bulk drug substances that may present significant safety risks when compounded. That listing affects whether licensed pharmacies may compound it, so availability depends on current federal rules and a provider's review.
Does LL-37 cause cancer?
There's no evidence it causes cancer in people. Preclinical studies show mixed effects: LL-37 appeared to promote tumor growth in some tissues, like ovarian and lung models, and suppress it in others. The FDA noted it can be protumorigenic in some tissues, so cancer history warrants caution.
Who should not take LL-37?
People with psoriasis, rosacea, lupus, rheumatoid arthritis or other autoimmune conditions have strong reasons for caution. So do people with a cancer history, those who are pregnant or breastfeeding, and anyone on immune-suppressing drugs. A licensed provider should review your full history first.
Can I raise LL-37 naturally instead?
Your body makes LL-37 on its own, and vitamin D helps switch on the gene that produces it. Correcting a vitamin D deficiency, under provider guidance, is the most studied natural route. Lab testing can show whether your vitamin D level is low before you supplement.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.